Royalty Report: Drugs, Pain, Therapeutic – Collection: 329681


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 6


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6

Primary Industries

  • Drugs
  • Pain
  • Therapeutic
  • Disease
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 329681

License Grant
University hereby grants the License to the Licensee and its Affiliates  (i) an exclusive, worldwide right and license under the Patent Rights and (ii) a non-exclusive, worldwide right and license to the University Know-How to (a) make, have made, use, research, develop, have developed, lease, market, offer to sell, sell, have sold, distribute, improve, import and export Licensed Products and Licensed Processes in the Field; and (b) otherwise practice the Invention in the Field.
License Property
US Patent #6,248,744 – Method for the treatment of pain, including chronic and female specific pain.

Invention means University#98-14 Sex Related Deference in Pain Relief from Spinal Compound (RJR 2403)

VCU Patents  S Patent #5,914,337 – Compounds and pharmaceutical compositions thereof for eliciting analgesic effects

Field of Use
Field of use is for the treatment of pain relief.

TC-2696 for the treatment of chronic or female-specific pain.  TC-2696 is a novel small molecule that we are developing as an oral treatment for acute post-operative pain.

IPSCIO Record ID: 230789

License Grant
University grants and Licensee accepts, further subject to any rights of the United States government, an exclusive license to all Universitys Patent Rights in the Territory, including the right to make, have made, use, sell, offer to sell, have sold, import, or distribute any Licensed Products in the Fields of Use and to practice any Licensed Processes in the Fields of Use.
License Property
Patent is for for the use of anti-inflammatory cytokines to fight chronic pain.

The patents are A Novel Gene Therapy Approach for Controlling Pathological Pain and Opiate Tolerance Spinal Production of the Anti-Inflammatory Cytokine, Interleukin-10, and, Suppression of Pathological Pain Plus Enhancement of Morphine Analgesia with the AntiInflammatory Cytokine Interleukin-10.

Field of Use
The license is for all Fields of Use, and the products relate to Suppression of Pathological Pain and Enhancement of Morphine Analgesia with Interleukin-10.

IPSCIO Record ID: 344574

License Grant
Licensor, , a not-for-profit corporation, grants, to the extent not prohibited by the United States Government or by contractual obligations  of research at Licensor
— an exclusive, worldwide, license under Licensors rights in Patent Rights to develop, have developed, make, have made, use, have used, sell, have sold, offer for sale, import and have imported Products;
— a non-exclusive, worldwide, license under Licensors rights in Technological Information;
— the right to sublicense Patent Rights exclusively licensed to Licensor.
License Property
Licensor has developed an invention pertaining to methods for decreasing or preventing pain, and is  the owner of all rights, title and interest in the patents and patent applications relating to the invention.

The patent is titled Methods of decreasing or preventing pain using spicamycin or derivatives thereof.

Field of Use
The field of use is pain reduction.

IPSCIO Record ID: 240632

License Grant
Licensor grants to Licensee a worldwide, exclusive, even to Licensor,  license, with the right to grant sublicenses, to use the Technology and Developments, to practice wider the Patent Rights, and to make, have made, use, have used, develop, have developed, offer for sale, sell, have sold, market, have marketed, import and have imported, Licensed Products, and to use or practice the Licensed Processes, in the Field of Use.  Under the agreement Licensee has exclusive worldwide rights to develop and commercialize Latranal for the treatment of acute and chronic muscle and tendon related pain.
License Property
The U.S. Patent Application is No. 3742-901-2-IPROV and related filings.

The license includes the active ingredients in Latranal, a drug for treating pain associated with muscle and tendon injury, from Licensor, which discovered that a topical formulation of two generically available compounds was effective for pain relief.

Field of Use
The Field of Use shall mean the management or treatment of any type of pain or muscular or skeletal discomfort arising from any cause, including without limitation trauma, diseases such as diabetes, herpes zoster, arthritis, osteoporosis, cancer chemotherapy or chemical injury.

IPSCIO Record ID: 5599

License Grant
The agreement granted a non-exclusive license and sublicense to use the oral formulations of these two product candidates and  granted a non-exclusive license to use its controlled release technologies.
License Property
Bicifadine is a serotonin-norepinephrine reuptake inhibitor (SNRI).  It has been developed as an analgesic and is currently under development for the treatment of various pain conditions. Phase III trials were completed in 2006 for treating chronic low back pain, and the drug is currently being tested to assess its efficacy in treating pain associated with osteoarthritis, acute post-surgical pain, neuropathic pain and pain associated with dental surgery. Its usefulness in surgical or dental pain is dubious, however, as most monoamine uptake-inhibiting antidepressants have little effect in treating acute pain–they are far more effective in cases of chronic, neuropathic pain.
Field of Use
The newly formed Licensee develops controlled release formulations of bicifadine for the treatment of pain and ocinaplon for the treatment of anxiety disorders and epilepsy.

IPSCIO Record ID: 230815

License Grant
Licensor shall grant the Licensee of Ireland a non-exclusive license, including the right to grant sublicense, of the Licensor Intellectual Property solely in the Field and in particular to make, have made, import, use, offer for sale and sell the Products in the Territory.

Licensor shall grant a non-exclusive sublicense of Licensors interests and entitlements solely in the Field under another Agreement in the anothers Know-How and the anothers patent Rights relating to the Compounds in the Territory, with the right to grants sublicenses.

License Property
Compounds shall mean the Licensor compounds named 220,075 and 273,547, the rights to which were licensed by Licensor pursuant to the ACY Agreement.

Product 220,075 shall mean , the twice daily oral formulation(s} using the Intellectual Property and incorporating the compound 220,075 (bicifadine- analgesic) utilizing the Technologies.

Product 273,547 shall mean the once daily oral formulation using the Intellectual Property and incorporating the compound 273,547 (nonbenzodiazapinen anxiolytic) utilizing the Technologies.

Field of Use
Field shall mean the research, development and commercialization of oral Controlled Release formulations of the Products.

IP relates to a controlled release formulations of bicifadine for the treatment of pain and ocinaplon for the treatment of anxiety disorders and epilepsy.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.